JP2020529440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529440A5 JP2020529440A5 JP2020505905A JP2020505905A JP2020529440A5 JP 2020529440 A5 JP2020529440 A5 JP 2020529440A5 JP 2020505905 A JP2020505905 A JP 2020505905A JP 2020505905 A JP2020505905 A JP 2020505905A JP 2020529440 A5 JP2020529440 A5 JP 2020529440A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- acceptable salt
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 10
- 239000003472 antidiabetic agent Substances 0.000 claims 6
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 208000030159 metabolic disease Diseases 0.000 claims 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims 3
- 229950004346 gaboxadol Drugs 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 2
- 229940123208 Biguanide Drugs 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 2
- 150000004283 biguanides Chemical class 0.000 claims 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000007410 oral glucose tolerance test Methods 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 150000001467 thiazolidinediones Chemical class 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541260P | 2017-08-04 | 2017-08-04 | |
| US62/541,260 | 2017-08-04 | ||
| PCT/US2018/044973 WO2019028234A1 (en) | 2017-08-04 | 2018-08-02 | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529440A JP2020529440A (ja) | 2020-10-08 |
| JP2020529440A5 true JP2020529440A5 (OSRAM) | 2021-09-09 |
Family
ID=65230918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505905A Pending JP2020529440A (ja) | 2017-08-04 | 2018-08-02 | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10813918B2 (OSRAM) |
| EP (1) | EP3648762A4 (OSRAM) |
| JP (1) | JP2020529440A (OSRAM) |
| KR (1) | KR20200047557A (OSRAM) |
| CN (1) | CN111201022A (OSRAM) |
| AU (1) | AU2018309049A1 (OSRAM) |
| CA (1) | CA3071939A1 (OSRAM) |
| IL (1) | IL272414A (OSRAM) |
| MX (1) | MX2020001342A (OSRAM) |
| WO (1) | WO2019028234A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200047557A (ko) | 2017-08-04 | 2020-05-07 | 오비드 테라퓨틱스 인크. | 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용 |
| IL322969A (en) | 2017-10-12 | 2025-10-01 | Novo Nordisk As | Semaglutide in medical therapy |
| JP2022514194A (ja) | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
| CN114786669A (zh) * | 2019-12-18 | 2022-07-22 | 奥维德医疗公司 | 用于1p36缺失综合征的治疗性治疗的加波沙朵 |
| EP4153549A2 (en) | 2020-05-20 | 2023-03-29 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| AU2023255685A1 (en) * | 2022-04-20 | 2024-12-05 | Aclipse Two Inc. | Treatment of gastrointestinal diseases |
| WO2025049710A1 (en) * | 2023-08-29 | 2025-03-06 | Aclipse Two Inc. | Pharmaceutical composition for use in the disease treatments |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| KR20070010136A (ko) * | 2004-04-02 | 2007-01-22 | 하. 룬트벡 아크티에 셀스카브 | 가복사돌을 이용한 손상된 호흡 기능의 치료 |
| US20080269278A1 (en) | 2004-04-02 | 2008-10-30 | H. Lundbeck A/S | Treatment of Impaired Respiratory Function with Gaboxadol |
| WO2006102093A1 (en) * | 2005-03-18 | 2006-09-28 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| DE102005020882A1 (de) * | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
| US20110046090A1 (en) | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US7635710B2 (en) * | 2006-02-15 | 2009-12-22 | Neurim Pharmaceuticals (1991) Ltd. | Pyrone-indole derivatives and process for their preparation |
| JP2010510314A (ja) | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス，エルエルシー | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 |
| TW200920358A (en) | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| WO2009117367A1 (en) * | 2008-03-18 | 2009-09-24 | Bristol-Myers Squibb Company | Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof |
| US9089531B2 (en) * | 2010-09-28 | 2015-07-28 | The Regents Of The University Of California | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes |
| AU2012296949B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| SMT202100340T1 (it) | 2014-06-06 | 2021-07-12 | Ovid Therapeutics Inc | Metodi per aumentare l'inibizione tonica e trattare l'insonnia secondaria |
| ES2664810T3 (es) | 2014-06-12 | 2018-04-23 | Pfizer Limited | Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA |
| JP2018502084A (ja) * | 2014-12-23 | 2018-01-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ベータ細胞への変換と組み合わせられたアルファ細胞の再生 |
| EP4541420A3 (en) | 2015-07-17 | 2025-06-25 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| US20170348232A1 (en) | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| JP2019524816A (ja) | 2016-08-11 | 2019-09-05 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | てんかん性障害の処置のための方法および組成物 |
| KR20200047557A (ko) | 2017-08-04 | 2020-05-07 | 오비드 테라퓨틱스 인크. | 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용 |
-
2018
- 2018-08-02 KR KR1020207006304A patent/KR20200047557A/ko not_active Withdrawn
- 2018-08-02 JP JP2020505905A patent/JP2020529440A/ja active Pending
- 2018-08-02 EP EP18840846.2A patent/EP3648762A4/en not_active Withdrawn
- 2018-08-02 MX MX2020001342A patent/MX2020001342A/es unknown
- 2018-08-02 CA CA3071939A patent/CA3071939A1/en active Pending
- 2018-08-02 AU AU2018309049A patent/AU2018309049A1/en not_active Abandoned
- 2018-08-02 US US16/053,081 patent/US10813918B2/en not_active Expired - Fee Related
- 2018-08-02 WO PCT/US2018/044973 patent/WO2019028234A1/en not_active Ceased
- 2018-08-02 CN CN201880065399.8A patent/CN111201022A/zh active Pending
-
2020
- 2020-02-02 IL IL272414A patent/IL272414A/en unknown
- 2020-10-08 US US17/066,389 patent/US11291658B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529440A5 (OSRAM) | ||
| JP4846063B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| CA2724133C (en) | Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine | |
| JP6066144B2 (ja) | 併用医薬 | |
| TW202202139A (zh) | 以２－〔（４－｛６－〔（４－氰基－２－氟苄基）氧基〕吡啶－２－基｝哌啶－１－基）甲基〕－１－〔（２ｓ）－氧雜環丁烷－２－基甲基〕－１ｈ－苯並咪唑－６－甲酸或其藥學上的鹽治療第２型糖尿病或肥胖症或體重過重 | |
| CN105407879A (zh) | 与帕金森病治疗相关的副作用的治疗 | |
| JP2018509419A5 (OSRAM) | ||
| TW202435860A (zh) | 用於治療疼痛的ｒ—ｍｄｍａ | |
| CN1921881A (zh) | 羟基化氨基酸用于治疗糖尿病的用途 | |
| JP6550160B2 (ja) | 糖尿病及び関連症状の治療のための方法及び組成物 | |
| TW201210586A (en) | Methods of using diacerein as an adjunctive therapy for diabetes | |
| WO2006116470A1 (en) | Use of metformin to counteract weight gain associated with aripiprazole or ziprasidone treatment | |
| JP2006508118A5 (OSRAM) | ||
| JPWO2007007757A1 (ja) | ＰＰＡＲγアゴニストを含有する医薬組成物 | |
| CA3100635A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| WO2011002012A1 (ja) | Sglt1阻害薬とインスリン抵抗性改善薬を組み合わせてなる医薬 | |
| JP2006519881A5 (OSRAM) | ||
| JP2009513593A (ja) | 糖尿病の治療 | |
| JP2017128545A (ja) | 併用医薬 | |
| KR20250158762A (ko) | 고혈당증 치료에서의 용도를 위한 베타-2-아드레날린 수용체 작용제 및 glp-1 수용체 작용제의 조합 | |
| US20060173045A1 (en) | Preventative or remedy for grinding | |
| TWI461192B (zh) | 降低血脂異常病患之糖化血色素的醫藥組成物 | |
| WO2012133693A1 (ja) | 糖尿病治療用の組合せ医薬 | |
| JP2005314380A5 (OSRAM) | ||
| JP2006063074A5 (OSRAM) |